Company intelligence / Profile preview

Cellix

Dublin, Ireland

Ownership: Private
Development stage: Other

Overview

Cellix develops and provides microfluidics-based devices and chips for cell analysis and diagnostics with primary applications in thrombosis, inflammation, and emerging QC for cell therapy manufacturing, including CAR-T cells. The company has been acquired by Randox Laboratories in 2023 and its technology is leveraged for new diagnostic test development.

Modalities: Device
Industry: Molecular Diagnostics

Partnerships

Fresenius (EASYGEN European consortium for CAR-T cell therapy workflows)

Beyond the preview

Go deeper on Cellix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellix.

Explore the full profile